US Drug Recall Register

FDA Drug Recalls

14,801 recalls, newest first

Class II · Moderate risk Terminated

L-Cysteine Hydrochloride Injection

Reason Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that the product sterility may be compromised.

Sandoz Inc NDC 66758-004-01 D-0140-2017
Class II · Moderate risk Terminated

Levoxyl

Reason Superpotent

Pfizer Inc. NDC 60793-860-01 D-0150-2017
Class III · Low risk Terminated

Amoxicillin for Oral suspension

Reason Labeling: Label Error on Declared Strength: Some bottles miss a color coded panel where the strength of the product is typically displayed.

West-Ward Pharmaceuticals Corp. NDC 0143-9887-01 D-0147-2017
Class III · Low risk Terminated

Diltiazem HCl Extended-release Capsules

Reason Failed Impurities/Degradation Specifications: OOS results for known compound.

Mylan Pharmaceuticals Inc. NDC 0378-5220-01 D-0151-2017
Class II · Moderate risk Terminated

Papa/Phen/Prost

Reason Lack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.

Fallon Wellness Pharmacy, L.L.C. D-0174-2017
Class II · Moderate risk Terminated

Papa/Phen/Prost

Reason Lack of Assurance of Sterility: product produced on a day there was an excursion in environmental monitoring data.

Fallon Wellness Pharmacy, L.L.C. D-0173-2017
Class II · Moderate risk Terminated

Metformin Hydrochloride Tablets

Reason Presence of Foreign Tablets/Capsules; report of Amlodipine Tablets found in 1000 count bottles of Metformin Hydrochloride Tablets USP

Ascend Laboratories LLC NDC 67877-217-10 D-0163-2017
Class III · Low risk Terminated

Qnasl

Reason Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.

Teva Pharmaceuticals USA NDC 59310-210-13 D-0171-2017
Class III · Low risk Terminated

Qnasl

Reason Failed Content Uniformity: Product was out of specification for spray content uniformity obtained during stability testing.

Teva Pharmaceuticals USA NDC 59310-206-06 D-0170-2017
Class II · Moderate risk Terminated

Fentanyl Citrate Injection

Reason Lack of Assurance of Sterility: Complaints of broken tips on the ampules.

Hospira Inc. NDC 0409-4093-32 D-0153-2017
Class I · High risk Terminated

Skinny Bee Diet capsules

Reason Marketed without an approved NDA/ANDA: presence of undeclared sibutramine, desmethylsibutramine (an active metabolite of sibutramine) and phenolphthalein.

Love My Tru Body D-0223-2017
Class II · Moderate risk Terminated

Phenazopyridine Hydrochloride Tablets

Reason CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.

Nationwide Laboratories, LLC NDC 42937-702-10 D-0168-2017
Class II · Moderate risk Terminated

Phenazopyridine Hydrochloride Tablets

Reason CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.

Nationwide Laboratories, LLC NDC 42937-701-10 D-0167-2017
Class II · Moderate risk Terminated

Salsalate Tablets

Reason CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.

Nationwide Laboratories, LLC NDC 42937-704-10 D-0166-2017
Class II · Moderate risk Terminated

Salsalate Tablets

Reason CGMP Deviations: manufactured under practices which may result in assay or content uniformity failures.

Nationwide Laboratories, LLC NDC 42937-703-18 D-0165-2017
Class III · Low risk Terminated

Kenalog

Reason Failed Stability Specifications: Low Out of Specification results for alcohol content.

Sun Pharmaceutical Industries, Inc. D-0148-2017
Class III · Low risk Terminated

Bupropion Hydrochloride Extended-Release Tablets

Reason Failed Dissolution Specifications: The firm was notified that there was a dissolution out of specification result on the 6 month stability samples.

Amerisource Health Services NDC 68001-264-05 D-0137-2017
Class II · Moderate risk Terminated

Phenazopyridine Hydrochloride Tablets

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-306-10 D-0162-2017
Class II · Moderate risk Terminated

Phenazopyridine Hydrochloride Tablets

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-304-10 D-0161-2017
Class II · Moderate risk Terminated

Indiomin MB URINARY ANTISEPTIC

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-315-10 D-0160-2017
Class II · Moderate risk Terminated

AZUPHEN MB URINARY ANTISEPTIC Capsules

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-314-10 D-0159-2017
Class II · Moderate risk Terminated

UROPHEN MB URINARY ANTISEPTIC Tablets

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-307-10 D-0158-2017
Class II · Moderate risk Terminated

URAMIT MB URINARY ANTISEPTIC Capsules

Reason CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

Burel Pharmaceuticals Inc NDC 35573-300-10 D-0157-2017